Assetmark Inc. Acquires 216 Shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE)

Assetmark Inc. increased its stake in shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) by 100.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 432 shares of the company’s stock after purchasing an additional 216 shares during the quarter. Assetmark Inc.’s holdings in iShares U.S. Pharmaceuticals ETF were worth $31,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Cultivar Capital Inc. bought a new stake in iShares U.S. Pharmaceuticals ETF in the second quarter worth about $25,000. Rothschild Investment LLC bought a new stake in shares of iShares U.S. Pharmaceuticals ETF during the 2nd quarter worth approximately $26,000. US Bancorp DE boosted its holdings in iShares U.S. Pharmaceuticals ETF by 137.0% during the 3rd quarter. US Bancorp DE now owns 384 shares of the company’s stock valued at $27,000 after acquiring an additional 222 shares during the period. Mather Group LLC. bought a new position in iShares U.S. Pharmaceuticals ETF in the 2nd quarter valued at $29,000. Finally, Comerica Bank increased its stake in iShares U.S. Pharmaceuticals ETF by 71.6% in the first quarter. Comerica Bank now owns 1,462 shares of the company’s stock worth $99,000 after purchasing an additional 610 shares during the period.

iShares U.S. Pharmaceuticals ETF Trading Up 0.1 %

NYSEARCA:IHE opened at $66.69 on Wednesday. The company has a market cap of $673.57 million, a price-to-earnings ratio of 6.49 and a beta of 0.58. iShares U.S. Pharmaceuticals ETF has a twelve month low of $57.62 and a twelve month high of $72.94. The stock has a fifty day simple moving average of $70.24 and a 200-day simple moving average of $68.72.

About iShares U.S. Pharmaceuticals ETF

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.